This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

EPO board revives Gilead patent, sends case back for review

By Inbar Preiss ( April 14, 2025, 16:04 GMT | Insight) -- Gilead Sciences, Inc. secured a partial victory at the European Patent Office after the Technical Board of Appeal upheld part of its patent on compounds that enhance the performance of other drugs, while also ruling against certain claims. Generic companies Teva Pharmaceutical Industries Ltd. and STADA Arzneimittel AG successfully challenged part of the patent, leading to the revocation of some claims. The case has been remitted for further review by the EPO Opposition Division, where remaining grounds for opposition will be assessed, potentially allowing generics to enter the market if the patent is ultimately revoked.An appeal from Gilead Sciences, Inc. was partially successful at the European Patent Office, as the Technical Board of Appeal salvaged part of the biopharmaceutical company’s patent related to compounds that improve the performance of other drugs....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections